Everest Organics Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Improved Price Appeal

As of 13 Feb 2026, Everest Organics trades at ₹401.85, down 5.41% from the previous close of ₹424.85. Despite this decline, the stock’s valuation metrics have improved significantly. The price-to-earnings (P/E) ratio stands at 58.95, a figure that, while still elevated, represents a marked improvement from prior levels that had contributed to a 'Sell' rating. The price-to-book value (P/BV) ratio is 5.38, indicating a premium over book value but aligning more closely with sector norms.

Enterprise value to EBITDA (EV/EBITDA) is 25.77, reflecting a premium valuation but one that is more reasonable compared to some peers. The PEG ratio, a critical measure of valuation relative to earnings growth, is notably low at 0.29, suggesting that the stock’s price growth potential may be undervalued relative to its earnings growth prospects.

Comparative Analysis with Industry Peers

When benchmarked against peers in the Pharmaceuticals & Biotechnology sector, Everest Organics’ valuation appears more balanced. For instance, Bliss GVS Pharma trades at a P/E of 20.82 and EV/EBITDA of 15.32, both considerably lower but accompanied by a higher PEG ratio of 0.87, indicating less growth expectation. Conversely, Shukra Pharma, rated as 'Very Expensive,' commands a P/E of 63.43 and EV/EBITDA of 52.05, underscoring Everest Organics’ relative moderation in valuation.

Other peers such as TTK Healthcare and Bajaj Healthcare are classified as 'Attractive' with P/E ratios below 23 and EV/EBITDA ratios ranging from 14.73 to 27.82, but their PEG ratios are substantially higher, reflecting different growth dynamics. Everest Organics’ PEG ratio of 0.29 stands out as a compelling indicator of value relative to growth, especially when juxtaposed with the sector’s average.

Financial Performance and Returns Contextualise Valuation

Everest Organics’ return on capital employed (ROCE) and return on equity (ROE) are modest at 9.06% and 9.13% respectively. These figures suggest steady but not exceptional profitability, which partly explains the cautious valuation stance. However, the company’s stock has delivered robust long-term returns, with a 3-year return of 300.65% and a 1-year return of 51.64%, far outpacing the Sensex’s respective returns of 37.89% and 9.85% over the same periods.

Shorter-term performance has been more volatile, with a year-to-date (YTD) decline of 20.55% against a Sensex drop of 1.81%, and a 1-month loss of 17.59%. This recent weakness may reflect broader market pressures or sector-specific challenges but also contributes to the improved valuation grade as the stock price adjusts downward.

Market Capitalisation and Quality Grades

Everest Organics holds a market capitalisation grade of 4, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score has improved to 53.0, upgrading its Mojo Grade from 'Sell' to 'Hold' as of 20 Jun 2025. This upgrade signals a more balanced risk-reward profile, supported by the recent valuation moderation and steady fundamentals.

While Everest Organics does not currently offer a dividend yield, its operational metrics and valuation suggest a focus on reinvestment and growth rather than income distribution. Investors should note the company’s EV to capital employed ratio of 3.63 and EV to sales ratio of 2.34, which are within reasonable bounds for the sector, indicating efficient capital utilisation relative to enterprise value.

Price Range and Volatility Considerations

The stock’s 52-week high of ₹536.40 and low of ₹210.95 illustrate significant price volatility over the past year. The current price near ₹401.85 positions the stock roughly 25% below its peak, offering a potential entry point for investors seeking exposure to the sector at a more attractive valuation. Intraday trading on 13 Feb 2026 saw a high of ₹424.45 and a low of ₹401.85, reflecting active price discovery and investor interest.

Such volatility is not uncommon in mid-cap pharmaceutical stocks, which are often sensitive to regulatory developments, product pipeline news, and broader market sentiment. The recent downward price adjustment has contributed to the improved valuation grade, suggesting that the market is recalibrating expectations in line with fundamentals.

Investor Takeaway: Balancing Growth Potential and Valuation

Everest Organics’ transition from an expensive to a fair valuation grade reflects a recalibration of market expectations amid recent price corrections. The company’s relatively high P/E and P/BV ratios remain above many peers, but its exceptionally low PEG ratio highlights attractive growth prospects relative to price. This suggests that while the stock is not a bargain basement buy, it offers a reasonable valuation for investors willing to accept mid-cap volatility in exchange for growth potential.

Long-term returns have been impressive, significantly outperforming the Sensex over three years, which supports a positive growth narrative. However, short-term price weakness and modest profitability metrics warrant a cautious approach. The upgrade in Mojo Grade to 'Hold' aligns with this balanced outlook, signalling neither a strong buy nor a sell recommendation but rather a watchful stance.

Investors should monitor sector developments, company earnings updates, and broader market trends to gauge whether Everest Organics can sustain its growth trajectory and justify its valuation premium. The stock’s current price level near ₹400 offers a more accessible entry point compared to its 52-week high, potentially rewarding patient investors over the medium term.

Conclusion

In summary, Everest Organics Ltd’s valuation parameters have shifted favourably, improving its price attractiveness relative to historical levels and peer benchmarks. The company’s solid long-term returns, combined with a fair valuation grade and upgraded Mojo rating, make it a noteworthy candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector’s growth potential. Nonetheless, the stock’s elevated P/E and moderate profitability metrics counsel prudence, underscoring the importance of comprehensive analysis before investment decisions.

Unlock special upgrade rates for a limited period. Start Saving Now →